Propofol-Associated Hypertriglyceridemia in Adults With Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation.
Journal
ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
1
9
2023
pubmed:
12
5
2023
entrez:
12
5
2023
Statut:
ppublish
Résumé
The incidence and risk factors for propofol-associated hypertriglyceridemia (HTG) in patients receiving extracorporeal membrane oxygenation (ECMO) have not been evaluated. The purpose of this study was to determine the incidence and risk factors for propofol-associated HTG in patients with acute respiratory distress syndrome (ARDS) on ECMO. This retrospective, cohort study included 167 adults admitted to a medical intensive care unit (ICU) from July 1, 2013 to September 1, 2021, who received 24 hours of concurrent propofol and ECMO therapy. The primary outcome was the incidence of propofol-associated HTG. Secondary outcomes included HTG risk factors, time to development and resolution of HTG, and incidence of pancreatitis. HTG occurred in 58 (34.7%) patients. Patients with HTG had longer durations of ECMO (19 vs. 13 days, p < 0.001), longer ICU length of stay (26.5 vs. 23 days, p = 0.002), and higher in-hospital mortality (51.7 vs. 34.9%, p = 0.047). Baseline sequential organ failure assessment score was associated with an increased risk of developing HTG (hazard ratio [HR] = 1.19, 95% confidence interval [CI] = 1.09-1.30; p < 0.001). Propofol-associated HTG occurred in one-third of patients receiving ECMO for ARDS. Higher baseline illness severity and ECMO duration were associated with an increased risk of propofol-associated HTG.
Identifiants
pubmed: 37172007
doi: 10.1097/MAT.0000000000001978
pii: 00002480-990000000-00239
doi:
Substances chimiques
Propofol
YI7VU623SF
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
856-862Informations de copyright
Copyright © ASAIO 2023.
Déclaration de conflit d'intérêts
Disclosure: The authors have no conflicts of interest to report.
Références
Bellani G, Laffey JG, Pham T, et al.; LUNG SAFE Investigators: Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 315: 788–800, 2016.
Lamm W, Nagler B, Hermann A, et al.: Propofol-based sedation does not negatively influence oxygenator running time compared to midazolam in patients with extracorporeal membrane oxygenation. Int J Artif Organs. 42: 233–240, 2019.
Chanques G, Constantin JM, Devlin JW, et al.: Analgesia and sedation in patients with ARDS. Intensive Care Med. 46: 2342–2356, 2020.
Thompson BT, Chambers RC, Liu KD: Acute respiratory distress syndrome. N Engl J Med. 377: 562–572, 2017.
Dreucean D, Harris JE, Voore P, Donahue KR: Approach to sedation and analgesia in COVID-19 patients on venovenous extracorporeal membrane oxygenation. Ann Pharmacother. 56: 73–82, 2022.
Patel M, Altshuler D, Lewis TC, et al.: Sedation requirements in patients on venovenous or venoarterial extracorporeal membrane oxygenation. Ann Pharmacother. 54: 122–130, 2020.
Devlin JW, Skrobik Y, Gélinas C, et al.: Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 46: e825–e873, 2018.
Dzierba AL, Abrams D, Madahar P, Muir J, Agerstrand C, Brodie D: Current practice and perceptions regarding pain, agitation and delirium management in patients receiving venovenous extracorporeal membrane oxygenation. J Crit Care. 53: 98–106, 2019.
Kovacevic MP, Dube KM, Lupi KE, Szumita PM, DeGrado JR: Evaluation of hypertriglyceridemia in critically ill patients with coronavirus disease 2019 receiving propofol. Crit Care Explor. 3: e0330, 2021.
Kenes MT, McSparron JI, Marshall VD, Renius K, Hyzy RC: Propofol-associated hypertriglyceridemia in coronavirus disease 2019 versus noncoronavirus disease 2019 acute respiratory distress syndrome. Crit Care Explor. 2: e0303, 2020.
Corrado MJ, Kovacevic MP, Dube KM, Lupi KE, Szumita PM, DeGrado JR: The incidence of propofol-induced hypertriglyceridemia and identification of associated risk factors. Crit Care Explor. 2: e0282, 2020.
Haffar S, Kaur RJ, Garg SK, et al.: Acute pancreatitis associated with intravenous administration of propofol: Evaluation of causality in a systematic review of the literature. Gastroenterol Rep (Oxf). 7: 13–23, 2019.
Roberts RJ, Barletta JF, Fong JJ, et al.: Incidence of propofol-related infusion syndrome in critically ill adults: A prospective, multicenter study. Crit Care. 13: R169, 2009.
Cheng V, Abdul-Aziz MH, Roberts JA, Shekar K: Optimising drug dosing in patients receiving extracorporeal membrane oxygenation. J Thorac Dis. 10(Suppl 5): S629–S641, 2018.
Hohlfelder B, Szumita PM, Lagambina S, Weinhouse G, Degrado JR: Safety of propofol for oxygenator exchange in extracorporeal membrane oxygenation. ASAIO J. 63: 179–184, 2017.
de Pretis N, Amodio A, Frulloni L: Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United Eur Gastroenterol J. 6: 649–655, 2018.
Devlin JW, Lau AK, Tanios MA: Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: An analysis of frequency and risk factors. Pharmacotherapy. 25: 1348–1352, 2005.
Devaud JC, Berger MM, Pannatier A, et al.: Hypertriglyceridemia: A potential side effect of propofol sedation in critical illness. Intensive Care Med. 38: 1990–1998, 2012.
Ranieri VM, Rubenfeld GD, Thompson BT, et al.; ARDS Definition Task Force: Acute respiratory distress syndrome: The Berlin definition. JAMA. 307: 2526–2533, 2012.
Grundy SM, Stone NJ, Bailey AL, et al.: 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 139: e1082–e1143, 2019.
Scherer J, Singh VP, Pitchumoni CS, Yadav D: Issues in hypertriglyceridemic pancreatitis: An update. J Clin Gastroenterol. 48: 195–203, 2014.
Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology: American College of Gastroenterology guideline: Management of acute pancreatitis. Am J Gastroenterol. 108: 1400–1415; 1416, 2013.
Austin PC, Lee DS, Fine JP: Introduction to the analysis of survival data in the presence of competing risks. Circulation. 133: 601–609, 2016.
Austin PC, Fine JP: Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 36: 4391–4400, 2017.
Pancholi P, Wu J, Lessen S, et al.: Triglyceride concentrations and their relationship to sedation choice and outcomes in mechanically ventilated patients receiving propofol. Ann Am Thorac Soc. 20: 94–101, 2023.
Muniraj T, Aslanian HR: Hypertriglyceridemia independent propofol-induced pancreatitis. Jop. 13: 451–453, 2012.
Grasselli G, Giani M, Scaravilli V, et al.: Volatile sedation for acute respiratory distress syndrome patients on venovenous extracorporeal membrane oxygenation and ultraprotective ventilation. Crit Care Explor. 3: e0310, 2021.
Crockett SD, Wani S, Gardner TB, Falck-Ytter Y, Barkun AN; American Gastroenterological Association Institute Clinical Guidelines Committee: American gastroenterological association institute guideline on initial management of acute pancreatitis. Gastroenterology. 154: 1096–1101, 2018.
Pratt EH, Mausert S, Wilson MD, et al.: A daily, respiratory therapist assessment of readiness to liberate from venovenous extracorporeal membrane oxygenation in patients with acute respiratory distress syndrome. Crit Care Explor. 3: e0584, 2021.